I do my best to keep this post up to date, but it's not easy. Not every company maintains a transparent and updated pipeline page. And several that do only disclose minimal details. So if you have information, please share it by email or in the comments.
Also, note that the number of drugs the title refers to doesn't include multiple indications for the same drug. Nor does it include "undisclosed" drugs. So it is a significant underestimate of the total pipeline. The full list below, however, shows everything, including multiple indications, and undisclosed compounds.
Company
Drug
Therapeutic area
Indication
Stage
Neurology
Amyotrophic lateral sclerosis and frontotemporal degeneration
Neurology
Charcot-Marie-Tooth disease type 1A adults
Oncology
B-cell non-Hodgkin lymphoma (atezolizumab combination)
Oncology
B-cell non-Hodgkin lymphoma (rituximab combination)
Rare disease
Facial angiofibroma
Oncology
B-cell non-Hodgkin lymphoma (monotherapy)
Oncology
Lymphangioleiomyomatosis
Oncology
Pancreatic tumors
Oncology
Squamous cell carcinoma
Neurology
Acute agitation in schizophrenia or bipolar disorder
Oncology
Neuroendocrine prostate cancer
Neurology
Acute agitation in Alzheimer's disease or dementia
Oncology
Pancreatic cancer
Neurology
Mood/anxiety disorders
Infectious disease
Dengue infection
Infectious disease
Chikungunya infection
Oncology
Prostate and ovarian cancers
Neurology
Alzheimer's disease
Rare disease
TTR amyloidosis
Neurology
Huntington's disease and tardive dyskinesia
Oncology
Acute myeloid leukemia
Oncology
Advanced or metastatic solid tumors, and non-Hodgkin's lymphoma
Oncology
Glioblastoma multiforma
Oncology
Epidermolysis bullosa
Oncology
Chemotherapy-induced alopecia
Oncology
Advanced or recurrent gynecological malignancies
Oncology
HNSCC dose escalation
Oncology
Personalized cancer immunotherapy
Neurology
Obsessive-compulsive disorder
Oncology
Acute myelogenous leukemia
Oncology
Neurofibromatosis type 2 (CereXis, Inc.)
Cardiology
Cerebral cavernous malformation
Rare disease
Adrenoleukodystrophy and adrenomyeloneuropathy
Infectious disease
Influenza
Neurology
Amyotrophic lateral sclerosis
Infectious disease
Multidrug-resistant gonorrhea
Infectious disease
Superficial skin infection
Infectious disease
Multidrug-resistant Candida infections
Infectious disease
Vaginosis
Oncology
Hepatocellular carcinoma
Oncology
Cardioprotection
Neurology
Opioid withdrawal
Oncology
Multiple tumor types
Neurology
Leber's hereditary optic neuropathy, Friedreich's ataxia
Neurology
Multiple sclerosis
Neurology
Multiple sclerosis
Oncology
Gioblastoma, melanoma, thyroid cancer
Oncology
Gioblastoma, melanoma, thyroid cancer
Neurology
Chronic fatigue syndrome/myalgic encephalomyelitis
Neurology
Leber's hereditary optic neuropathy, Friedreich's ataxia
Metabolic disease
Undisclosed
Infectious disease
Staphylococcus a
Neurology
Alzheimer's disease
Infectious disease
Chagas disease
Infectious disease
M. tuberculosis A
Infectious disease
C. Neoformans
Infectious disease
Hepatitis B
Oncology
HNSCC combination therapy
Oncology
Multiple oncology indications
Oncology
Ovarian expansion
Metabolic disease
Wilson disease
Metabolic disease
Undisclosed
Infectious disease
Undisclosed
Infectious disease
Cystic fibrosis, pseudomonas aeruginosa
Infectious disease
Skin infections, staphylococcus aureus
Oncology
Personalized cancer immunotherapy
Infectious disease
3 undisclosed pathogens
Oncology
Personalized cancer immunotherapy
Rare disease
Neuroblastoma
Rare disease
CDKL5 syndrome
Rare disease
Pitt Hopkins
Rare disease
Barth syndrome
Oncology
Prostate and ovarian cancers
Oncology
RAS pancreatic cancer
Oncology
Second line metastatic ovarian cancer
Oncology
Second line metastatic melanoma
Neurology
Charcot-Marie-Tooth disease type 1A pediatric
Neurology
Amyotrophic lateral sclerosis
Oncology
High-grade serous ovarian cancer
Oncology
Triple negative breast cancer
Oncology
Radiation sensitizer
Neurology
Neuroinflammation
Cardiology
Pulmonary hypertension
Hematology
Hereditary hemorrhagic
Oncology
Von hippel-linda
Neurology
Charcot-marie-tooth
Infectious disease
Clostridium difficile
Undisclosed
Undisclosed indication
Metabolic disease
Mucolipidosis
Cardiology
Dilated cardiomyopathy
Neurology
Tay-sachs/sandhoff disease
Biogerontology
Senescence
Dermatology
Darier disease
Oncology
Hematologic malignancies, primary brain tumors, neuroblastoma
Oncology
Metastatic breast cancer, primary brain tumors
Rare disease
Phenylketonuria
Rare disease
Niemann-Pick disease type C
Neurology
Parkinson's disease
Metabolic disease
Non-alcoholic steatohepatitis
Neurology
Parkinson's disease
Metabolic disease
Non-alcoholic steatohepatitis
Neurology
Parkinson's disease
Metabolic disease
Non-alcoholic steatohepatitis
Inflammation and immunology
Undisclosed immune condition 1
Fibrosis
Undisclosed fibrosis 4
Fibrosis
Undisclosed fibrosis 3
Inflammation and immunology
Undisclosed immune condition 2
Inflammation and immunology
Undisclosed immune condition 3
Inflammation and immunology
Undisclosed inflammatory condition 1
Fibrosis
Undisclosed fibrosis 2
Oncology
Non-small-cell lung carcinoma
Metabolic disease
Undisclosed metabolic condition 1
Oncology
Tumor myeloid cells
Oncology
Protein degradation
Infectious disease
Gram - bacteria
Cardiology
Undisclosed cardiovascular indication
Oncology
Undisclosed cardiovascular indication
Neurology
Amyotrophic lateral sclerosis
Neurology
Amyotrophic lateral sclerosis
Neurology
Neurodegenerative diseases
Infectious disease
Anti-viral
Infectious disease
Tuberculosis
Oncology
Acute myeloid leukemia
Oncology
Multiple myeloma
Oncology
Small cell lung cancer
Neurology
Alzheimer's disease
Metabolic disease
Non-alcoholic steatohepatitis
Inflammation and immunology
Rheumatoid arthritis
Infectious disease
Gram negative bacteria
Infectious disease
Tuberculosis
Cardiology
Undisclosed cardiovascular
Oncology
Undisclosed immuno-oncology
Infectious disease
ESKAPE pathogens
Metabolic disease
Undisclosed
Metabolic disease
Undisclosed
Metabolic disease
Undisclosed
Gastroenterology
Undisclosed
Gastroenterology
Undisclosed
Infectious disease
Undisclosed
Oncology
Multiple oncology indications
Ophthalmology
Undisclosed retinopathy
Inflammation and immunology
Undisclosed
Respiratory
Chronic obstructive pulmonary disease
Inflammation and immunology
Undisclosed
Inflammation and immunology
Undisclosed
Oncology
Undisclosed solid tumors
Oncology
Advanced melanoma, KRAS-mutant pancreatic ductal adenocarcinoma
Oncology
KRAS-driven tumors
Oncology
Renal cell carcinoma
Oncology
BTK-resistant / relapsed lymphomas
Undisclosed
Reversal of T cell exhaustion
Metabolic disease
Mitochondria disease
Oncology
Undisclosed cancer
Neurology
Parkinson's disease
Oncology
Undisclosed cancer
Oncology
Undisclosed cancer
Oncology
Undisclosed cancer
Oncology
Undisclosed cancer
Oncology
Undisclosed cancer
Oncology
Undisclosed cancer
Metabolic disease
Non-alcoholic steatohepatitis
Infectious disease
Tuberculosis
Oncology
Undisclosed cancer
Fibrosis
Undisclosed fibrotic disease
Inflammation and immunology
Rheumatoid arthritis
Oncology
Undisclosed cancer
Oncology
Undisclosed oncology indication 5
Oncology
Undisclosed oncology indication 6
Dermatology
Undisclosed dermatology condition 1
Neurology
Undisclosed neurological condition 1
Rare disease
Undisclosed rare disease 1
Oncology
Undisclosed oncology indication 4
Inflammation and immunology
Autoimmune disease
Inflammation and immunology
Systemic lupus erythematosus
Cardiology
Anticoagulation
And there you have it, the AI in drug discovery pipeline, as far as I know it. Did I get anything wrong? Am I missing anything? Please let me know in the comments or by email.